Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Treprostinil
Drug ID BADD_D02268
Description Treprostinil is a synthetic analogue of prostacyclin, used to treat pulmonary hypertension.
Indications and Usage For use as a continuous subcutaneous infusion or intravenous infusion (for those not able to tolerate a subcutaneous infusion) for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise.
Marketing Status approved; investigational
ATC Code B01AC21
DrugBank ID DB00374
KEGG ID D06213
MeSH ID C427248
PubChem ID 6918140
TTD Drug ID D01WUA
NDC Product Code 0703-0696; 0781-3430; 11014-0094; 66302-350; 66302-648; 66302-748; 66302-361; 66302-363; 66302-620; 66302-720; 0703-0676; 43598-646; 43598-647; 66302-302; 66302-325; 66302-616; 66302-362; 0703-0666; 14501-0015; 42023-209; 62332-515; 66302-110; 66302-300; 66302-610; 54893-0024; 43598-649; 62332-514; 62332-517; 66302-102; 66302-206; 66302-732; 58159-041; 68245-0008; 43598-648; 66302-120; 66302-600; 66302-650; 66302-764; 0703-0686; 0781-3420; 0781-3425; 81861-0029; 66302-101; 66302-310; 66302-630; 66302-664; 0781-3427; 42023-206; 66302-105; 66302-640; 42023-207; 62332-516; 66302-632; 66302-716; 42023-208
UNII RUM6K67ESG
Synonyms treprostinil | ((1R,2R,3AS,9AS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3A,4,9,9A-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate | treprostinil sodium | trepostinil sodium | Orenitram | UT-15 | UT-15C | Remodulin | treprostinil diolamine | treprostinil diolamin | treprostinil diethanolamine
Chemical Information
Molecular Formula C23H34O5
CAS Registry Number 81846-19-7
SMILES CCCCCC(CCC1C(CC2C1CC3=C(C2)C(=CC=C3)OCC(=O)O)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intra-abdominal haemorrhage07.12.02.008; 12.01.17.011; 24.07.02.0350.000082%
Malnutrition14.03.02.0040.000123%-
Cardiac valve disease02.07.02.0010.000082%-
Decreased appetite08.01.09.028; 14.03.01.0050.010700%
Feeling of body temperature change08.01.09.0120.000280%-
Pseudomonas infection11.02.12.001---
Ill-defined disorder08.01.03.049---
Blood disorder01.05.01.0040.000082%-
Adjustment disorder19.23.01.0010.000082%-
Autoimmune disorder10.04.04.0030.000123%
Disease progression08.01.03.0380.004532%
Drug intolerance08.06.01.0130.009927%-
Obstructive airways disorder22.03.01.0110.000222%-
Sinus disorder22.04.06.0020.000559%
Poor quality sleep17.15.04.002; 19.02.05.0050.000740%-
Arterial occlusive disease24.04.02.0210.000082%-
Infusion site extravasation08.02.05.007; 12.07.05.0080.001464%
Pulmonary arterial hypertension22.06.01.002; 24.08.03.0030.012271%-
Infusion site haematoma08.02.05.001; 12.07.05.001; 24.07.01.0420.000123%-
Infusion site haemorrhage08.02.05.018; 12.07.05.018; 24.07.01.0580.002591%-
Infusion site irritation08.02.05.010; 12.07.05.0110.001143%-
Infusion site urticaria08.02.05.021; 10.01.06.010; 12.07.05.021; 23.04.02.0100.000280%-
Haematological malignancy01.13.01.003; 16.21.01.0020.000082%-
Brain injury17.11.01.003; 19.07.03.0070.000164%-
Oropharyngeal discomfort07.05.05.008; 22.12.03.0150.000181%-
Oropharyngeal pain07.05.05.004; 22.12.03.0160.005963%
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.12.03.0360.000280%
Functional gastrointestinal disorder07.11.01.0160.000222%-
Catheter site extravasation08.02.02.012; 12.07.02.0120.000280%-
The 12th Page    First    Pre   12 13 14 15    Next   Last    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene